New Pill Cuts LDL Cholesterol by 60% — Cardiologists Weigh In on Heart-Attack Prevention

A breakthrough in cholesterol treatment has arrived: a new daily pill has been shown in trials to cut “bad” LDL cholesterol by up to 60%. For millions of people whose cholesterol remains stubbornly high despite using statins, this could mark a major shift. But does it mean heart attacks will also drop? Cardiologists say the early promise is exciting — but caution that there’s more to uncover.

What the Pill Does and How It Works

The experimental drug, known as enlicitide, targets a liver protein called PCSK9. Normally, PCSK9 slows down the body’s ability to clear LDL cholesterol from the bloodstream. By blocking PCSK9, enlicitide helps the liver remove more LDL, causing levels to plummet.
In a Phase 3 clinical trial of about 2,900 adults (average age ~63) who were already on statins, participants who took enlicitide along with their usual medications achieved reductions in LDL of up to 60% after 24 weeks of daily treatment — compared to a placebo group. Many also achieved LDL levels well below 70 mg/dL, and more than two-thirds had reductions of 50% or more.
What makes this especially noteworthy is that previous PCSK9-targeting treatments came in injectable form (often every two weeks or month). The potential for a daily pill offers greater convenience and broader access.

Can This Pill Really Reduce Heart Attacks?

The good news

High LDL cholesterol is a major risk factor for heart disease and heart attacks. Lowering LDL has been shown repeatedly to reduce cardiovascular events over time. So, a drug that chops LDL by 50-60% is a big deal in theory.

The cautions

However, cardiologists point out that the trial so far has shown LDL reduction, but not yet proven that heart-attacks or strokes drop because of this pill. The outcome-studies (looking explicitly at heart attack rates) are still ongoing.
Also, even though the pill is powerful, it’s not a substitute for statins, according to experts. Statins remain the foundation of cholesterol treatment. The pill is meant to add on, especially for patients whose LDL remains high despite statins or who cannot tolerate injectable treatments.
Finally, long-term safety, durability of effect, and cost/availability remain to be seen. The convenience of a pill is attractive, but real-world adoption will depend on many factors.

Why This Matters for Patients

When statins don’t do enough

Many individuals on statin therapy still have LDL levels above recommended targets. Genetic factors, other medications, organ conditions, or simply very high baseline LDL can blunt statin effects. For them, having a potent additional option is valuable.

Convenience and access

Injectable PCSK9 inhibitors have been very effective, but their need for injections, refrigeration (in some cases), and higher cost have limited widespread use. A daily pill may overcome those barriers.

Potential impact on guidelines

If further trials confirm that the pill not only lowers LDL but also reduces heart-attack and stroke risk, it could lead to guideline changes, more prescriptions, and better outcomes for many. It could also shift how cardiologists treat high-risk patients.

Things to Keep in Mind

• Still experimental: Though the results are strong for LDL lowering, full approval will require demonstration of long-term benefits and safety.

• Complement, not replace: This pill is viewed as a “plus” treatment — not replacing lifestyle changes or statins, but building on them.

• Eligibility will matter: The trial focused on patients who already had high risk or had elevated LDL despite standard treatment. It’s unclear yet if the drug will be for general population or only high-risk groups.

• Cost and availability: Novel therapies often come with high cost initially and may face access issues in lower-income regions or with certain insurance schemes.

• Lifestyle still key: Lowering LDL via medication is powerful, but diet, exercise, weight control, and addressing other risk factors (blood pressure, smoking, diabetes) remain foundational for heart health.

Final Thoughts

The new pill cutting LDL by up to 60% is a very promising development in cardiovascular medicine. It opens the possibility of more patients reaching safe cholesterol levels more easily and with better convenience. But until outcome trials confirm that it reduces heart attacks and strokes, cardiologists are calling for cautious optimism. For now, this is a major step — not yet the finish line.

Read More: 48 Fitness Hacks That Changed My Life After 40